The EASL SLD Summit 2025 offered a comprehensive exploration of steatotic liver disease, over three days. The programme integrated practical clinical education with the latest research updates.

The first day opened with a session titled “The trajectory of people living with Steatotic Liver Disease: a clinical update and consensus.” This session featured talks covering aspects from prevention to end-stage disease management, including key stakeholders.

Also on the first day, the summit hosted the “Endpoint Conference on ALD and MetALD in Phase 2 and 3 clinical trials". This conference focused on improving clinical trial design, execution, and evaluation for ALD and MetALD, aiming to enhance patient outcomes. It addressed the progression from fibrosis to decompensated cirrhosis, the use of invasive versus non-invasive tests as endpoints, and the role of MASH methodologies in informing clinical trials for ALD and MetALD.

On 24 and 25 January, the summit’s core programme covered the latest innovations and insights in MASLD, MetALD, and ALD. It presented a holistic understanding of SLD, from research findings to the practical implications for patient care.